Serum pentosidine as an indicator of Alzheimer's disease

Article type: Research Article

Authors: Meli, M.^a | Perier, C.^a | Ferron, C.^b | Parssegny, F.^c | Denis, C.^d | Gonthier, R.^c | Laurent, B.^e | Reynaud, E.^a | Frey, J.^a | Chamson, A.^{a; *}

Affiliations: [a] Service de Biochimie, Hôpital Nord, CHU Saint-Etienne, Saint-Etienne, France | [b] Service de Gériatrie, Hôpital Saint-Jean-Bonnefonds, CHU Saint-Etienne, France | [c] Service de Gériatrie, Hôpital de La Charité, CHU Saint-Etienne, France | [d] Service de Physiologie, Hôpital Saint-Jean-Bonnefonds, CHU Saint-Etienne, France | [e] Service de Neurologie, Hôpital de Bellevue, CHU Saint-Etienne, France

Correspondence: [*] Corresponding author: A. Chamson, Laboratoire de Biochimie, Hôpital Nord, Avenue A. Raimond, 42055 Saint-Etienne Cedex 2, France. Tel.: +33 4 77 12 77 40; Fax: +33 4 77 42 14 89; E-mail: [email protected].

Abstract: Pentosidine, an advanced glycation end product (AGE), was assayed by HPLC in serum proteins from patients with Alzheimer type dementia (AD), patients with diabetes mellitus (D), and healthy (C) age-matched old subjects (mean age from each group = 84 years). Serum pentosidine was significantly different between the three groups despite similar renal function (serum creatinine < 160 μmol/L). In all groups of patients, pentosidine was independent of glycated hemoglobin (HbA1C) and the early glycation marker fructosamine and appeared to be an independent marker, mainly bound to serum albumin. Pentosidine could be an important factor useful for the diagnosis of Alzheimer's disease.

Keywords: pentosidine, AGE, Alzheimer's disease

DOI: 10.3233/JAD-2002-4203

Journal: Journal of Alzheimer's Disease, vol. 4, no. 2, pp. 93-96, 2002